Spero Therapeutics develops tebipenem HBr, an oral antibiotic in development for complicated urinary tract infections in adults. SPRO reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Cantor Fitzgerald | Initiated | Buy | |
| Sep 14 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How SPRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in SPRO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRO is in one of them and how their past SPRO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SPRO in an article yet. Here's the latest on the wider market.
About Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments for rare diseases and diseases with high unmet need. Its main product candidate is tebipenem HBr, an oral tablet antibiotic in development to treat complicated urinary tract infections in adults with limited oral treatment options. The company has no products approved for sale, and GSK is developing and commercializing tebipenem HBr under a license agreement. Its intended users are adult patients and the physicians who treat them.
- Headquarters
- Cambridge, MA